Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?

Toshio Tanaka1

  • 1Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine & Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan. ttanak@imed3.med.osaka-u.ac.jp

Immunotherapy
|July 9, 2013
PubMed
Summary

Tocilizumab (TCZ) treatment for rheumatoid arthritis (RA) patients showed a trend toward increasing the regulatory T cell (Treg) to T helper type 17 (Th17) cell ratio. Further studies are needed to confirm this effect in RA.